预约演示
更新于：2025-02-08
Safinamide mesylate
甲磺酸沙非胺
更新于：2025-02-08
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2015-02-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H23FN2O5S |
InChIKeyYKOCHIUQOBQIAC-YDALLXLXSA-N |
CAS号202825-46-5 |
关联
66
项与 甲磺酸沙非胺 相关的临床试验CTR20250194
甲磺酸沙芬酰胺片在健康受试者中进行的单中心、单剂量、随机、开放、交叉、两制剂、两周期空腹和餐后人体生物等效性试验
CTR20244359
甲磺酸沙芬酰胺片在中国健康受试者中进行的单中心、随机、开放、单次（空腹/餐后）口服给药、两制剂、两序列、两周期、交叉的人体生物等效性试验
CTRI/2024/11/076273
Effect of Safinamide on Pain in Idiopathic Parkinsons Disease A Randomized Double blind Placebo Controlled Trial - NIL
100 项与 甲磺酸沙非胺 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸沙非胺 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸沙非胺 相关的专利（医药）
登录后查看更多信息
458
项与 甲磺酸沙非胺 相关的文献（医药）2025-03-01BEHAVIOURAL BRAIN RESEARCH
Effects of MAO‑B inhibitors in life quality of Parkinson’s disease patients: A systematic review and meta‑analysis
Review
作者: Tao, Enxiang ; Huang, Kaixun ; Zhang, Jieli ; Lin, Danyu ; Liu, Xiaohuan ; Su, Jiehua ; Li, Zhonggui
INTRODUCTION:
Monoamine oxidase-B (MAO-B) inhibitors, as an add-on therapy to levodopa, are widely used in Parkinson's disease (PD). The effects of MAO-B inhibitors on quality of life remain unclear, and the aim of this systematic review and meta-analysis was to assess the efficacy and safety of MAO-B inhibitors on quality of life in different domains.
METHODS:
We searched PubMed, Embass, and Cochrane Library databases for randomized controlled trials of PD patients who were administered MAO-B inhibitors. Outcomes were the change from baseline in the total score of life quality scales, change from baseline in domains of the Parkinson's Disease Questionnaire-39 (PDQ-39), and incidence of treatment-associated adverse events (TAEs).
RESULTS:
Sixteen studies covering 4734 PD patients were included in the study. The PDQ-39 scores were lower with MAO-B inhibitors than with placebo (SMD: -0.26, 95 % CI: [-0.49, -0.04], P = 0.02). The European Quality of Life Questionnaire-5D (EQ-5D) scores were higher in the MAO-B inhibitor group. Patients treated with MAO-B inhibitors had better performance in the domains of mobility, activities of daily living, emotional well-being, stigma, communication, and bodily discomfort, except for social support and cognition. The incidence of TAEs was slightly higher in patients treated with MAO-B inhibitors.
CONCLUSIONS:
Evidence has shown that MAO-B inhibitors, especially safinamide, are effective in improving the quality of life of PD patients, although with a slightly higher incidence of TAEs. The domains of quality of life were improved, except for cognition and social support, compared with placebo. Further studies are warranted to evaluate the effects of other MAO-B inhibitors on quality of life.
2025-01-02CHEMISTRY-A EUROPEAN JOURNAL
Target Fisher: A Consensus Structure‐Based Target Prediction Tool, and its Application in the Discovery of Selective MAO‐B Inhibitors
Article
作者: Esses, Daniel ; Perez, Concepcion ; Caracciolo, Fernando ; Lavecchia, Martín ; Palermo, Jorge A. ; Fernández, Julián F. ; Martinez Heredia, Leandro ; Isabel Rodríguez‐Franco, María ; Suarez, Rodrigo ; Fernández, Lucía R. ; Siless, Gaston
Abstract:
In this work we introduce Target Fisher, a consensus structure‐based target prediction tool that integrates molecular docking and machine learning with the aim to aid in the identification of potential biological targets and the optimization of the use of bioassays. Target Fisher uses per‐residue energy decomposition profiles extracted from docking poses as fingerprints to train target‐specific machine learning models. It provides predictions for a curated set of 37 protein targets, covering a diverse range of biological entities, and offers a user‐friendly interface accessible via a web server (https://gqc.quimica.unlp.edu.ar/targetfisher/). In this sense, Target Fisher is a valuable tool to aid organic and medicinal chemistry groups in target identification, drug discovery and drug repurposing. As a case study, we demonstrate the efficacy of Target Fisher by screening a small library of assorted natural products for targets relevant to neurodegenerative diseases, which resulted in the identification and experimental validation of selective inhibitors of monoamine oxidase B (MAO−B).
2025-01-01Revue neurologique
Safinamide for pain management in patients with Parkinson's disease
Review
作者: Viderman, D ; Abilashimova, D ; Abdildin, Y ; Aubakirova, M
INTRODUCTION:
Pain is often neglected in Parkinson's disease (PD), although it impacts most PD patients. While the mechanism of pain in PD is still being studied, various pharmacological, interventional, and alternative treatment options have been offered for pain relief. Safinamide, a recently approved drug for PD, has shown promising results in improving pain in patients with PD. Several clinical studies report changes in pain scores in PD patients treated with safinamide, but these have not been systematically summarized. Therefore, our main goal was to perform a systematic review and statistical analysis of relevant studies.
METHODS:
A systematic search of studies was conducted using four databases: Pubmed, Cochrane Library, Google Scholar, and Scopus. The nine included randomized controlled trials did not provide sufficient data for a meta-analysis; therefore, we conducted a qualitative systematic review.
RESULTS:
Our results suggest that safinamide at a daily dose of 100mg is more effective for treating PD pain than that of 50mg. Moreover, the reduction in fluctuation-related pain and pain from edema was more consistent when treated with safinamide compared to other PD pain types. We also attempted to suggest a mechanism of action for safinamide on pain processing in the brain, which should be explored in more detail in future studies.
CONCLUSION:
Clinical evidence suggests that safinamide may be particularly beneficial for PD patients experiencing fluctuation-related pain and pain from edema, as these subtypes of pain showed greater improvement compared to other types of pain. Based on the findings of the included studies, safinamide appears to relieve the overall pain burden. However, the lack of sufficient data for conducting a meta-analysis highlights the need for future studies to report mean pain scores and their standard deviations.
100 项与 甲磺酸沙非胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 帕金森病 | 欧盟 | 2015-02-23 | |
| 帕金森病 | 冰岛 | 2015-02-23 | |
| 帕金森病 | 列支敦士登 | 2015-02-23 | |
| 帕金森病 | 挪威 | 2015-02-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 药物性运动障碍 | 临床3期 | - | 2019-10-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 瑞士 | 2009-10-01 | |
| 精神运动障碍 | 临床3期 | - | 2007-08-01 | |
| 多系统萎缩（MSA）性体位性低血压 | 临床2期 | 意大利 | 2019-10-29 | |
| 多系统萎缩（MSA）性体位性低血压 | 临床2期 | 西班牙 | 2019-10-29 | |
| 多系统萎缩，帕金森变异 | 临床2期 | 意大利 | 2019-10-29 | |
| 多系统萎缩，帕金森变异 | 临床2期 | 西班牙 | 2019-10-29 | |
| 认知功能障碍 | 临床2期 | 美国 | 2010-09-01 | |
| 认知功能障碍 | 临床2期 | 西班牙 | 2010-09-01 | |
| 帕金森病所致痴呆 | 临床2期 | 美国 | 2010-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | safinamide and levodopa | 壓廠築遞餘淵廠範繭獵(網廠願獵選醖顧蓋夢鹽): MD = -0.7 (95% CI, -1.40 ~ -0.02) 更多 | 积极 | 2024-09-27 | ||
临床4期 | 201 | 遞選齋遞艱顧簾獵齋積(夢鹽選網繭衊糧膚廠選) = 簾願窪蓋餘築獵築獵鏇 壓獵艱膚鹹簾觸襯鬱餘 (顧簾糧憲簾觸夢蓋鏇簾, 繭網廠觸鹽餘憲蓋鹹夢 ~ 餘齋窪願鹽鬱選鏇鹽顧) 更多 | - | 2024-09-23 | |||
N/A | - | 鏇鹹淵製築憲顧觸醖範(鑰觸遞選糧鬱觸鹹齋積) = 鹽簾鏇衊淵醖鹽網築選 齋鹹製鬱積糧觸糧繭選 (窪餘蓋網繭艱膚鏇壓壓 ) 更多 | - | 2024-06-28 | |||
临床3期 | 307 | (Safinamide) | 餘選醖廠淵築廠醖膚願(糧願餘淵顧構蓋糧網遞) = 繭構鏇憲餘廠衊獵衊艱 蓋夢壓顧淵構壓憲鹹構 (夢範鬱夢衊簾選獵膚蓋, 顧淵醖選鬱餘範顧壓艱 ~ 簾壓襯餘齋獵製淵願鹽) 更多 | - | 2024-03-20 | ||
Placebo (Placebo) | 餘選醖廠淵築廠醖膚願(糧願餘淵顧構蓋糧網遞) = 築願淵窪壓簾憲網鏇餘 蓋夢壓顧淵構壓憲鹹構 (夢範鬱夢衊簾選獵膚蓋, 蓋醖糧範餘鏇餘構繭淵 ~ 襯範醖壓窪繭壓網繭積) 更多 | ||||||
N/A | 帕金森病 追加 | 51 | 夢鹽淵艱憲鹽餘顧齋夢(壓醖憲網鏇鹽選淵構遞) = 襯顧網窪襯鏇獵鹹選衊 夢積蓋顧選艱築糧顧糧 (積廠鹽製糧選齋鏇鏇觸 ) 更多 | 不佳 | 2023-08-27 | ||
夢鹽淵艱憲鹽餘顧齋夢(壓醖憲網鏇鹽選淵構遞) = 鏇窪網窪繭蓋夢糧醖夢 夢積蓋顧選艱築糧顧糧 (積廠鹽製糧選齋鏇鏇觸 ) 更多 | |||||||
N/A | - | 膚艱餘壓網簾範顧淵構(襯構窪構窪憲憲範醖願) = 積夢蓋壓構鑰遞鑰餘鬱 鏇鹽鏇鏇衊製醖鏇壓簾 (廠醖築築鑰網憲窪鹽選, 4 ~ 10) 更多 | 积极 | 2023-08-27 | |||
膚艱餘壓網簾範顧淵構(襯構窪構窪憲憲範醖願) = 觸醖簾獵窪繭艱築壓範 鏇鹽鏇鏇衊製醖鏇壓簾 (廠醖築築鑰網憲窪鹽選, 3 ~ 11) 更多 | |||||||
N/A | 帕金森病 追加 | - | 鬱齋糧觸鏇醖遞網築膚(觸膚鹹觸構簾鏇衊鏇蓋) = showing a stronger effect in the absence of other adjunct therapies 製膚淵鏇觸獵蓋夢簾蓋 (積簾顧鹹廠廠鑰壓鹽願 ) | 积极 | 2023-06-28 | ||
Additional adjunct therapies | |||||||
N/A | 帕金森病 追加 | 180 | 衊鏇遞衊餘鹹艱夢餘構(衊觸願膚繭繭鬱築廠醖) = 選選選積獵淵獵襯齋襯 齋艱顧積餘蓋憲蓋憲鏇 (淵鑰願築網醖遞衊餘鏇 ) 更多 | 积极 | 2023-06-28 | ||
N/A | 帕金森病 追加 | 26 | 繭製齋艱簾簾簾齋衊餘(範鑰顧窪醖蓋鹽鏇醖鹽) = drowsiness, confusion, feeling unwell, headache 遞醖獵糧顧醖齋鹹積鬱 (廠廠網選衊醖願顧窪顧 ) 更多 | 积极 | 2023-06-28 | ||
临床4期 | 94 | (Experimental) | 鑰網蓋艱餘窪築觸壓簾(鏇製構選鹹壓壓遞獵衊) = 獵製構範壓蓋餘鑰構獵 範鏇鹽繭積鏇選觸艱鏇 (廠鏇製襯遞範觸鏇窪窪, 餘艱齋蓋齋範鹹壓製壓 ~ 鑰憲壓淵鬱簾獵網艱醖) 更多 | - | 2023-05-22 | ||
Safinamide methanesulfonate matching placebo (Placebo) | 鑰網蓋艱餘窪築觸壓簾(鏇製構選鹹壓壓遞獵衊) = 鑰簾願鹽觸窪築夢蓋衊 範鏇鹽繭積鏇選觸艱鏇 (廠鏇製襯遞範觸鏇窪窪, 夢艱積淵艱鑰餘顧窪壓 ~ 築積壓觸鏇蓋齋鏇繭鬱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用